ArticleJournal of personalized medicine2021

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.

Wen-Jing Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.